Macrocyclic HIV-1 Protease Inhibitors Resisting Drug Resistance
Solution Overview
Problem
Current antiretroviral therapies for HIV-1 infection face challenges such as high dosing frequency, toxicity, and the rapid emergence of drug-resistant HIV variants, limiting their long-term efficacy and necessitating the development of potent, less toxic drugs that can maintain effectiveness against resistant strains.
Innovation Solution
Development of novel protease inhibitors with functionalities that interact with the amino acid backbone of HIV-1 protease and flexible macrocyclic groups, which effectively inhibit both proteolytic activity and dimerization of the protease, even in resistant variants, through dual modes of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current protease inhibitors are used in HAART regimens, then HIV replication is suppressed and life expectancy is extended, but drug resistance emerges rapidly and treatment failure occurs
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific functional groups (amino acid backbone interactors and flexible macrocyclic groups) that target particular regions of the HIV-1 protease enzyme. This localized interaction strategy enhances binding affinity and specificity, allowing the drug to maintain efficacy against both wild-type and resistant variants by precisely engaging with conserved structural elements of the protease active site.
Solution Approach 2:
The patent employs composite materials by combining multiple functional moieties within a single inhibitor molecule: (1) amino acid backbone interaction groups that form hydrogen bonds with conserved protease residues, (2) flexible macrocyclic groups that adapt to the protease binding pocket, and (3) hydrophobic regions that interact with the enzyme's hydrophobic core. This composite structure creates a multi-functional inhibitor that simultaneously achieves high affinity, selectivity, and resistance to mutation-driven inactivation.
2Reliability
If high frequency dosing and combination therapy are implemented, then viral suppression is achieved, but toxicity increases and adherence becomes difficult
Solution Approach 1:
The patent applies parameter changes by optimizing the pharmacokinetic properties of the inhibitor through molecular structure modification. The flexible macrocyclic groups and amino acid backbone interactors are designed to enhance metabolic stability and prolong half-life, enabling less frequent dosing while maintaining effective plasma concentrations. This parameter optimization reduces the cumulative toxic burden associated with high-frequency dosing regimens.
3Reliability
If multiple drug classes are combined in HAART, then treatment efficacy improves, but pill burden increases and tolerability decreases
Solution Approach 1:
The patent applies universality by designing a multi-functional inhibitor that simultaneously addresses multiple therapeutic needs: (1) potent inhibition of HIV-1 protease activity, (2) prevention of resistance development through multi-point binding, (3) extended half-life for reduced dosing frequency, and (4) favorable safety profile. This single agent performs multiple functions that traditionally required multiple drugs, potentially simplifying the treatment regimen and improving adherence.
Data Source
AI summary
Macrocycle containing carbamate compounds that inhibit HIV proteolytic enzymes and processes for preparing them are described. Compositions and methods for treating a patient infected with HIV are described.